I agree that this site is using cookies. You can find further informations here.
X
Holko, Przemysław
57  results:
Search for persons X
?
1

Provision of special diets to children in public nurseries ..:

Piórecka, Beata ; Kozioł-Kozakowska, Agnieszka ; Holko, Przemysław..
Frontiers in Nutrition.  11 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
2

Clinical aspects of reimbursement policies for orphan drugs..:

Jakubowski, Szczepan ; Kawalec, Pawel ; Holko, Przemyslaw...
Frontiers in Pharmacology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
3

Comparative safety of tyrosine kinase inhibitors in the tre..:

Krawczyk, Kinga ; Śladowska, Katarzyna ; Holko, Przemysław.
Frontiers in Pharmacology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
4

Out-of-pocket expenses of patients with inflammatory bowel ..:

Holko, Przemysław ; Kawalec, Paweł ; Sajak-Szczerba, Magdalena..
The European Journal of Health Economics.  24 (2022)  7 - p. 1073-1083 , 2022
Link: https://doi.org/10.1007/..
 
?
5

Indirect Costs of Inflammatory Bowel Diseases: A Comparison..:

Holko, Przemysław ; Kawalec, Paweł ; Sajak-Szczerba, Magdalena..
Inflammatory Bowel Diseases.  29 (2022)  5 - p. 752-762 , 2022
Link: https://doi.org/10.1093/..
 
?
6

Wykorzystanie baz danych Narodowego Funduszu Zdrowia przy o..:

Holko, Przemysław ; Kawalec, Paweł
Zdrowie Publiczne i Zarządzanie.  20 (2022)  2 - p. 25-33 , 2022
Link: https://doi.org/10.4467/..
 
?
7

Comparative safety of high-efficacy disease-modifying thera..:

Śladowska, Katarzyna ; Kawalec, Paweł ; Holko, Przemysław.
Neurological Sciences.  43 (2022)  9 - p. 5479-5500 , 2022
Link: https://doi.org/10.1007/..
 
?
8

Impact of Biologic Treatment of Crohn's Disease on the Rate..:

Holko, Przemysław ; Kawalec, Paweł ; Pilc, Andrzej
Frontiers in Pharmacology.  9 (2018)  - p. , 2018
Link: https://doi.org/10.3389/..
 
?
9

Cost-Effectiveness Analysis of Crohn's Disease Treatment wi..:

Holko, Przemysław ; Kawalec, Paweł ; Pilc, Andrzej
PharmacoEconomics.  36 (2018)  7 - p. 853-865 , 2018
Link: https://doi.org/10.1007/..
 
?
10

Comment on: "Forecasting Pharmaceutical Prices for Economic..:

Holko, Przemysław
PharmacoEconomics - Open.  1 (2017)  1 - p. 69-70 , 2017
Link: https://doi.org/10.1007/..
 
?
11

Health-Related Quality of Life Impairment and Indirect Cost..:

Holko, Przemysław ; Kawalec, Paweł ; Mossakowska, Małgorzata..
PLOS ONE.  11 (2016)  12 - p. e0168586 , 2016
Link: https://doi.org/10.1371/..
 
?
12

A Comment on Craig et al.: ''Retigabine for the Adjunctive ..:

Holko, Przemysław ; Kawalec, Paweł
PharmacoEconomics.  31 (2013)  6 - p. 533-535 , 2013
Link: https://doi.org/10.1007/..
 
?
13

Cost-utility analysis of Ruconest ® (conestat alfa) compare..:

Kawalec, Paweł ; Holko, Przemysław ; Paszulewicz, Anna
Advances in Dermatology and Allergology.  3 (2013)  - p. 152-158 , 2013
Link: https://doi.org/10.5114/..
 
?
14

Administration of Conestat Alfa, Human C1 Esterase Inhibito..:

Kawalec, Paweł ; Holko, Przemysław ; Paszulewicz, Anna.
Advances in Respiratory Medicine.  81 (2013)  2 - p. 95-104 , 2013
Link: https://doi.org/10.5603/..
 
?
15

Cost effectiveness and cost utility of the noncoding blood ..:

Kawalec, P ; Przemyslaw Holko
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.  , 2011
Link: https://doi.org/10.2147/..
 
1-15